Iconovo’s CEO interviewed by DNB Carnegie
Iconovo’s CEO Anders Månsson, was recently interviewed by DNB Carnegie to discuss the company’s latest quarterly report.
Author: jerker.stigsson@cloomy.se
Anders Månsson at DNB Carnegie Småbolagsdag
Iconovo’s new Interim CEO, Anders Månsson, made his first official appearance for the company when he presented Iconovo at DNB Carnegie’s Småbolagsdag on 27 November.
Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million
The Board of Directors of Iconovo AB (“Iconovo” or the “Company”) has today resolved on a directed share issue of approximately SEK 25 million (the “Directed Issue”), and on an issue of shares of approximately SEK 24.6 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”, together the “Issues”).
Iconovo appoints Anders Månsson as new CEO
Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, has today appointed Anders Månsson as interim CEO of Iconovo AB. The Board of Directors has in parallel initiated a process to recruit a permanent CEO, for which Anders also is a candidate.